|
Medarex is building the ultimate monoclonal antibody. Its UltiMAb technology utilizes transgenic mice whose antibody gene expression is suppressed to create fully human monoclonal antibodies (single-source proteins). Medarex has more than 40 antibodies for cancer, rheumatoid arthritis, and other autoimmune, inflammatory, and infectious diseases in clinical trials or pre-trial stages. The company has partnerships with numerous pharma and biotech firms including Genmab, which has licensed antibody therapies for leukemia, arthritis, and other conditions. Other development partners include Pfizer, Amgen, Eli Lilly, and Kirin. Another major collaborator, Bristol-Myers Squibb, acquired Medarex for $2.4 billion in 2009.
|
| | | Contact Information | |
Address: |
707 State Rd.
Princeton, NJ 08540-1437
| | Phone: | 609-430-2880 | | Fax: | 609-430-2850 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 52.30 M | | Revenue Growth (1 yr): | (-7.00%) | | Employees (2008): | 488 | | Employee Growth (1 yr): | (-2.40%) |
|
|
Key People
| | • |
Chairman Emeritus:
Irwin Lerner
| | • |
Chairman, President, and CEO:
Howard H. Pien
| | • |
SVP Finance and Administration and CFO:
Christian S. Schade
|
|
|
